Rules-Based Medicine (RBM) specializes in advanced immunoassay technologies to support drug development and clinical trials, particularly in the realm of neurodegenerative disorders and idiopathic pulmonary fibrosis (IPF). The company utilizes Single-Molecule Array (Simoa™) technology, which allows for ultrasensitive detection of biomarkers, enabling the diagnosis and monitoring of neurological conditions. Additionally, RBM has developed Luminex-based sandwich immunoassays for 11 specific biomarkers related to IPF, ensuring that these assays are highly optimized and validated for clinical applications.

RBM operates as a CLIA-certified laboratory, emphasizing quality and reproducibility in its testing processes. The company employs a multi-analyte profiling (MAP) approach, which facilitates the simultaneous measurement of hundreds of human proteins. Their rigorous quality control measures include automated and manual inspections at various stages of the assay process, ensuring the reliability of the data produced. With a comprehensive menu of over 300 assays, RBM is positioned to provide tailored biomarker testing solutions that meet the complex needs of clinical research.

United States

Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory.

Rules-Based Medicine

Company Details